Ottawa Study Shows sEVs Deliver siRNA to Kidneys, Brain
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Ottawa researchers showed that sEVs derived from specific cell types naturally home to particular organs, enabling targeted siRNA delivery.
- sEVs injected intravenously delivered siRNA to mouse kidneys, reducing disease symptoms in a chronic kidney disease model.
- sEVs administered directly into the central nervous system delivered siRNA to the brain, improving outcomes in a neurodegenerative disease model.
- The study confirmed that the same tissue‑targeting strategy worked in larger animal models, with efficacy scaling predictably with body size and remaining robust across species.
- siRNA therapeutics can silence disease‑causing genes for up to six months with a single dose, according to the researchers.
- Dr. Derrick Gibbings is seeking industry or academic partners to launch clinical trials, prioritizing severe kidney disease linked to APOL1 gene variants.
- APOL1‑related kidney disease is a focus for translation, but scaling up sEV production and extending siRNA durability are identified as major hurdles.
Why it matters: Patients with APOL1‑related chronic kidney disease gain a viable therapeutic avenue, while biotech firms that can scale sEV manufacturing stand to secure a market for a tissue‑specific RNA delivery platform. This also addresses the previous industry's failure to develop a universal sEV carrier, shifting the focus to organ‑targeted solutions.
